Tag: Scott Trerotola
Lutonix for dysfunctional arteriovenous fistulae shows improved primary patency vs. plain...
Interim twelve-month data from the Lutonix AV Clinical Trial indicate that treatment of dysfunctional arteriovenous (AV) fistulae with Bard’s Lutonix drug-coated balloon (DCB) produces...
Lutonix AV results provide tailwind for drug-coated balloons in dysfunctional arteriovenous...
Scott Trerotola presented the first release of eight-month data from the Lutonix AV trial at the Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany)...
Promising early results for Lutonix US IDE trial in obstructed AV...
The first US randomised controlled trial for drug-coated balloon use for arteriovenous fistula obstructions for 50 years, the Lutonix (Bard) IDE trial was a...
